Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Effect of rosuvastatin on cytokines after traumatic head injury.

Sánchez-Aguilar M, Tapia-Pérez JH, Sánchez-Rodríguez JJ, Viñas-Ríos JM, Martínez-Pérez P, de la Cruz-Mendoza E, Sánchez-Reyna M, Torres-Corzo JG, Gordillo-Moscoso A.

J Neurosurg. 2013 Mar;118(3):669-75. doi: 10.3171/2012.12.JNS121084. Epub 2013 Jan 4.

PMID:
23289819
2.

Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758).

Tapia-Perez J, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J.

J Neurotrauma. 2008 Aug;25(8):1011-7. doi: 10.1089/neu.2008.0554.

3.

Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach.

Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT.

J Neurotrauma. 2012 May 1;29(7):1388-400. doi: 10.1089/neu.2011.2117. Epub 2012 Apr 2.

PMID:
22233347
4.

NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.

Satoh M, Tabuchi T, Itoh T, Nakamura M.

Clin Sci (Lond). 2014 Feb;126(3):233-41. doi: 10.1042/CS20130043.

PMID:
23944632
5.

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.

6.

Letter to the Editor: traumatic head injury.

Chao TH, Lin CJ, Liu H, Chu CC, Hueng DY.

J Neurosurg. 2013 May;118(5):1149. doi: 10.3171/2013.1.JNS1353. Epub 2013 Mar 15. No abstract available.

PMID:
23495877
7.

Effect of rosuvastatin compared with other statins on lipid levels and National Cholesterol Education Program goal attainment for low-density lipoprotein cholesterol in a usual care setting.

Bullano MF, Wertz DA, Yang GW, Kamat S, Borok GM, Gandhi S, McDonough KL, Willey VJ.

Pharmacotherapy. 2006 Apr;26(4):469-78.

PMID:
16553504
8.

Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.

Xu Y, Tang T, Ding Y, Yao R, Xie J, Liao M, Xiao H, Chen Y, Yu X, Fu M, Liao Y, Zhao G, Cheng X.

Am J Med Sci. 2010 Aug;340(2):121-7. doi: 10.1097/MAJ.0b013e3181e2b353.

PMID:
20588182
9.

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH).

ter Avest E, Abbink EJ, Holewijn S, de Graaf J, Tack CJ, Stalenhoef AF.

Curr Med Res Opin. 2005 Sep;21(9):1469-76.

PMID:
16197666
10.

Response.

Sánchez-Aguilar M, Gordillo-Moscoso A, Tapia-Pérez JH, Torres-Corzo JG.

J Neurosurg. 2013 May;118(5):1149-50. No abstract available.

PMID:
23776935
11.
12.
13.

Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells.

Lazzerini PE, Capperucci C, Spreafico A, Capecchi PL, Niccolini S, Ferrata P, Frediani B, Galeazzi M, Laghi-Pasini F.

Joint Bone Spine. 2013 Mar;80(2):195-200. doi: 10.1016/j.jbspin.2012.07.007. Epub 2012 Sep 19.

PMID:
22999910
15.

Rosuvastatin: a review of its use in the management of dyslipidemia.

Scott LJ, Curran MP, Figgitt DP.

Am J Cardiovasc Drugs. 2004;4(2):117-38. Review. Erratum in: Am J Cardiovasc Drugs. 2005;5(2):130.

PMID:
15049723
16.

Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial.

Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators..

Circulation. 2010 Jan 19;121(2):306-14. doi: 10.1161/CIRCULATIONAHA.109.900027. Epub 2010 Jan 4.

17.

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators..

Lancet. 2008 Oct 4;372(9645):1231-9. doi: 10.1016/S0140-6736(08)61240-4. Epub 2008 Aug 29.

PMID:
18757089
18.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group..

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
19.

Rosuvastatin for sepsis-associated acute respiratory distress syndrome.

National Heart, Lung, and Blood Institute ARDS Clinical Trials Network., Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT.

N Engl J Med. 2014 Jun 5;370(23):2191-200. doi: 10.1056/NEJMoa1401520. Epub 2014 May 18.

20.

Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study.

Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, Siasos G, Papageorgiou N, Papadimitriou CA, Dimopoulos MA, Stefanadis C.

Atherosclerosis. 2010 May;210(1):194-8. doi: 10.1016/j.atherosclerosis.2009.10.046. Epub 2009 Nov 10.

PMID:
19962701

Supplemental Content

Support Center